[
  {
    "title": "Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications",
    "url": "https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: 67% of patients completed assessments, reducing discontinuation risk by 30%."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN [ROADMAP]**: Integrate AI-driven reminders to optimize patient engagement and data quality."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL [ðŸŸ¡ NOTABLE]**: Growing adoption of PROs in oncology trials as regulatory pressure increases."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: Self-selection bias may skew results toward healthier patients, impacting clinical validity."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC",
    "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: 3 FDA-approved ATTR-CM therapies now rely on PRO endpoints to demonstrate patient benefit."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN [ROADMAP]**: Integrate AI-driven analytics to predict patient adherence and optimize ePRO workflows."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL [ðŸ”´ URGENT]**: New FDA guidance prioritizes PRO integration in cardiovascular trials by Q1 2025."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: Self-selection bias could inflate PRO improvements, requiring rigorous study design safeguards."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer",
    "url": "https://ascopubs.org/doi/10.1200/OA-25-00051",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: 67% completion rate achieved with proactive reminders, enhancing data quality."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN [SHIP NOW]**: Integrate daily push notifications to maintain engagement throughout treatment."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL [ðŸŸ¡ NOTABLE]**: Growing emphasis on PROs in regulatory guidelines for cancer trials."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: Self-selection bias may underrepresent severe cases, affecting generalizability."
      }
    ],
    "model": "granite4:tiny-h"
  }
]